| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5000 | 2011 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3186 | 2013 |
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... The Lancet 375 (9724), 1437-1446, 2010 | 1305 | 2010 |
| Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade VK Arora, E Schenkein, R Murali, SK Subudhi, J Wongvipat, MD Balbas, ... Cell 155 (6), 1309-1322, 2013 | 990 | 2013 |
| VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer J Gao, JF Ward, CA Pettaway, LZ Shi, SK Subudhi, LM Vence, H Zhao, ... Nature medicine 23 (5), 551-555, 2017 | 564 | 2017 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 519 | 2018 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 377 | 2015 |
| Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer CN Sternberg, K Fizazi, F Saad, ND Shore, U De Giorgi, DF Penson, ... New England Journal of Medicine 382 (23), 2197-2206, 2020 | 360 | 2020 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 356 | 2020 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 343 | 2014 |
| Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant … CJ Logothetis, E Basch, A Molina, K Fizazi, SA North, KN Chi, RJ Jones, ... The lancet oncology 13 (12), 1210-1217, 2012 | 324 | 2012 |
| PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3 A Salameh, AK Lee, M Cardó-Vila, DN Nunes, E Efstathiou, FI Staquicini, ... Proceedings of the National Academy of Sciences 112 (27), 8403-8408, 2015 | 272 | 2015 |
| Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer E Efstathiou, M Titus, S Wen, A Hoang, M Karlou, R Ashe, SM Tu, ... European urology 67 (1), 53-60, 2015 | 269 | 2015 |
| Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology JP Droz, M Aapro, L Balducci, H Boyle, T Van den Broeck, P Cathcart, ... The lancet oncology 15 (9), e404-e414, 2014 | 262 | 2014 |
| Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial JC Araujo, GC Trudel, F Saad, AJ Armstrong, YY Evan, J Bellmunt, ... The lancet oncology 14 (13), 1307-1316, 2013 | 250 | 2013 |
| Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response CJ Ryan, S Shah, E Efstathiou, MR Smith, ME Taplin, GJ Bubley, ... Clinical Cancer Research 17 (14), 4854-4861, 2011 | 245 | 2011 |
| Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone E Efstathiou, M Titus, D Tsavachidou, V Tzelepi, S Wen, A Hoang, ... Journal of clinical oncology 30 (6), 637, 2012 | 225 | 2012 |
| Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma MA Dimopoulos, G Hamilos, A Zomas, D Gika, E Efstathiou, V Grigoraki, ... The Hematology Journal 5 (2), 112-117, 2004 | 193 | 2004 |
| Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms ZG Li, P Mathew, J Yang, MW Starbuck, AJ Zurita, J Liu, C Sikes, ... The Journal of clinical investigation 118 (8), 2697-2710, 2008 | 190 | 2008 |
| Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients HJ Boyle, S Alibhai, L Decoster, E Efstathiou, K Fizazi, N Mottet, S Oudard, ... European Journal of Cancer 116, 116-136, 2019 | 172 | 2019 |
